Could an ADHD drug beat cancer fatigue in kids?

NCT ID NCT06905587

Recruiting now Symptom relief Sponsor: Odense University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether methylphenidate, a drug used for ADHD, can reduce severe fatigue in people who had a brain tumor as a child or teen. Fifty survivors aged 6 and older will receive either the drug or a placebo in a crossover design. The goal is to see if it improves energy and thinking, offering a new option for a common, tough side effect.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: methylphenidate (a stimulant drug used for ADHD)
What this could lead to: If it works, this could provide an evidence-based treatment option for severe fatigue in young brain tumor survivors, improving their daily energy and quality of life.
What could go wrong: This is a small, early-phase trial (50 people) testing a drug that may cause side effects like sleep problems or appetite loss. The benefit may be modest or not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAIN TUMOR, PEDIATRIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRAIN TUMOR, PEDIATRIC CANCER-RELATED FATIGUE METHYLPHENIDATE

Contacts and locations

Locations

Aalborg University Hospital
NOT_YET_RECRUITING

Aalborg, 9000, Denmark
Aarhus University Hospital
RECRUITING

Aarhus, 8200, Denmark
Odense University Hospital
RECRUITING

Odense, 5000, Denmark
Rigshospitalet
RECRUITING

Copenhagen, 2100, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.